Published July 1, 2021 | Version v1
Journal article Restricted

Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland

  • 1. Health Information and Quality Authority, Dublin, Ireland; Trinity College Dublin, Institute of Population Health, Tallaght, Dublin, Ireland.
  • 2. Health Information and Quality Authority, Dublin, Ireland.
  • 3. Trinity College Dublin, Institute of Population Health, Tallaght, Dublin, Ireland.
  • 4. Health Information and Quality Authority, Dublin, Ireland; Trinity College Dublin, Department of Pharmacology & Therapeutics, Trinity Health Sciences, Dublin, Ireland.

Description

Objectives: To estimate the cost-effectiveness of introducing a publicly funded pre-exposure prophylaxis (PrEP) program in Ireland.

Methods: We constructed a state-transition Markov model. This was a cross-sectional population model that tracked all HIV-negative men who have sex with men (MSM) in Ireland over their lifetime. Access to a publicly funded PrEP program (medications + frequent monitoring) in high-risk MSM was compared with no PrEP. The primary outcome measure was the incremental cost-effectiveness ratio (ICER).

Results: In the base case, introducing a PrEP program was considered cost saving and provided significant health benefits to the population. Univariate sensitivity analysis demonstrated that PrEP efficacy and HIV incidence had the greatest impact on cost-effectiveness. Including an increase in sexually transmitted infections had a negligible impact on the results. Efficacy was a significant driver in the model. PrEP was cost saving at all efficacy values above 60%, and at the lowest reported efficacy in MSM (44% in the iPrEX trial), the ICER was €4711/QALY (highly cost-effective). Event-based dosing (administration during high-risk periods only) was associated with additional cost savings. We estimated that 1705 individuals (95% CI: 617-3452) would join the program in year 1. The incremental budget impact was €1.5m (95% CI: €0.5m to €3m) in the first year and €5.4m over 5 years (95% CI: €1.8m to €11.5m), with 173 cases of HIV averted over 5 years.

Conclusion: We found that the introduction of a PrEP program would be considered cost saving in the first cost-effectiveness analysis of its kind in Ireland.

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.